Drug Trial Radar · NCT00555321
Belatacept in Liver Transplant Recipients
Last checked: Nov 20, 2026Latest source record: Oct 18, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
260
Actual
Start
Jan 2008
Primary completion
Mar 2010
Study completion Jun 2011
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Nov 8, 2007
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this clinical research study is to evaluate the effects of belatacept, relative to tacrolimus, on the incidence of rejection, graft loss and death in subjects receiving a liver transplant
Conditions
- Immunosuppression in Solid Organ Transplant
Interventions
TacrolimusDrug
Capsules, Oral, dosed to achieve 12 hour trough level of 6-12 ng/mL, twice daily, 52 weeks (Short Term \[ST\]), in accordance with local practice and the package insert, 4 years (Long-Term Extension \[LTE\])
BasiliximabDrug
Intravenous (IV), 20 mg, Day1 and Day 5
Belatacept More Intensive (MI)Drug
Intravenous (IV), 10 mg/kg on Days 1, 3 and 5, and at Weeks 2, 4, 6, 8, 10, 12, 16, 20, and 24. After 6 months (24 weeks) 5 mg/kg, every 4 weeks, 52 weeks (Short term \[ST\]), 5 mg/kg, every 4 weeks, 4 years (Long-term extension \[LTE\])
Belatacept Less Intensive (LI)Drug
Intravenous (IV), 10 mg/kg on Days 1, 3 and 5, and at Weeks 2, 4, 8 and 12. After 3 months (12 weeks) 5 mg/kg, every 4 weeks, 52 weeks (Short term \[ST\]), 5 mg/kg, every 4 weeks, 4 years (Long-Term Extension(LTE)
Mycophenolate Mofetil (MMF)Drug
Intravenous (IV)/Capsules, IV/Oral, 1-2g/day, 52 weeks (Short term \[ST\]), ≤ 1 g/day, 4 years (Long-term extension \[LTE\])
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Who Experienced at Least One Episode of Acute Rejection (AR), Graft Loss, or Death by 6 Months Post-transplantTime frame: At 6 months posttransplant
- Number of Participants Who Had Adverse Events (AEs), Death, Serious AEs (SAEs) or Were Discontinued Due to AEs (Includes Long Term Extension [LTE] Data)Time frame: Day 1 (randomization) to Week 104 + within 56 Days after the last infusion/dose, Deaths were monitored up to database lock (20-June-2011)
- Number of Participants Who Had AEs of Special Interest During the LTETime frame: Day 1 (randomization) through database lock (20-June-2011)
- Number of Participants With Marked Hematology Abnormalities During the LTETime frame: Every 4 weeks from Week 53 to Week 104.
- Number of Participants With Marked Liver and Kidney Function Abnormalities During the LTETime frame: Every 4 weeks from Week 53 to Week 104.
- Number of Participants With Marked Electrolytes, Protein and Metabolic Test Abnormalities During the LTETime frame: Every 4 weeks from Week 53 to Week 104.
Locations
42 sites in 9 countries. Site status is shown where the registry gives one.
Mayo Clinic Hospital
Phoenix, Arizona
Usc University Hospital
Los Angeles, California
University Of California San Francisco Medical Center
San Francisco, California
Mayo Clinic Transplant Department
Jacksonville, Florida
Lifelink Healthcare Institute
Tampa, Florida
Emory University Hospital
Atlanta, Georgia
Northwestern University Feinberg School Of Medicine
Chicago, Illinois
Tulane Center For Abdominal Transplant
New Orleans, Louisiana
Henry Ford Hospital
Detriot, Michigan
University Of Minnesota
Minneapolis, Minnesota
Washington University School Of Medicine
St Louis, Missouri
Nyu School Of Medicine
New York, New York
Westchester Medical Center
Valhalla, New York
Carolinas Medical Center
Charlotte, North Carolina
Univ. Of Cin. Coll. Of Med.
Cincinnati, Ohio
Integris-Baptist Medical Ctr.
Oklahoma City, Oklahoma
Hospital Of The University Of Pennsylvania
Philadelphia, Pennsylvania
Baylor University Medical Center
Dallas, Texas
Froedtert Memorial Lutheran Hospital
Milwaukee, Wisconsin
Local Institution
Ciudad de Buenos Aires, Buenos Aires, Argentina
Local Institution
Vienna, Austria
Local Institution
Curitiba, Paraná, Brazil
Local Institution
Rio de Janeiro, Rio de Janeiro, Brazil
Local Institution
Centro-Porto Alegre, Rio Grande do Sul, Brazil
Local Institution
Edmonton, Alberta, Canada
Local Institution
Toronto, Ontario, Canada
Local Institution
Clichy, France
Local Institution
Lyon, France
Local Institution
Montpellier, France
Local Institution
Paris, France
Local Institution
Toulouse, France
Local Institution
Villejuif, France
Local Institution
Berlin, Germany
Local Institution
Hamburg, Germany
Local Institution
Hanover, Germany
Local Institution
Heidelberg, Germany
Local Institution
Tübingen, Germany
Local Institution
Bergamo, Italy
Local Institution
Padova, Italy
Local Institution
Pisa, Italy
Showing 40 of 42 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.